Morgan Stanley’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-467,442
| Closed | -$15.8M | – | 8264 |
|
|
2021
Q2 | $15.8M | Sell |
467,442
-744,198
| -61% | -$19M | ﹤0.01% | 2430 |
|
|
2021
Q1 | $28.3M | Sell |
1,211,640
-14,215
| -1% | -$431K | ﹤0.01% | 1604 |
|
|
2020
Q4 | $35.3M | Buy |
1,225,855
+1,076,528
| +721% | +$27.1M | 0.01% | 1356 |
|
|
2020
Q3 | $3.02M | Buy |
149,327
+139,959
| +1,494% | +$3.42M | ﹤0.01% | 3244 |
|
|
2020
Q2 | $281K | Buy |
9,368
+6,818
| +267% | +$246K | ﹤0.01% | 4908 |
|
|
2020
Q1 | $80K | Sell |
2,550
-34,401
| -93% | -$1.2M | ﹤0.01% | 5280 |
|
|
2019
Q4 | $1.74M | Buy |
36,951
+31,125
| +534% | +$899K | ﹤0.01% | 4140 |
|
|
2019
Q3 | $38K | Buy |
5,826
+5,755
| +8,106% | +$48.1K | ﹤0.01% | 5825 |
|
|
2019
Q2 | $1K | Sell |
71
-2,392
| -97% | -$26.6K | ﹤0.01% | 6602 |
|
|
2019
Q1 | $33K | Sell |
2,463
-6,452
| -72% | -$57.8K | ﹤0.01% | 5844 |
|
|
2018
Q4 | $36K | Buy |
8,915
+149
| +2% | +$898 | ﹤0.01% | 5852 |
|
|
2018
Q3 | $59K | Buy |
+8,766
| New | +$83.5K | ﹤0.01% | 5837 |
|
Morgan Stanley's CNST Position: Q3 2021 in Review
Morgan Stanley sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 467,442 shares — an estimated $15.8M sold.
Morgan Stanley first reported a position in CNST in Q3 2018 and held it in 12 quarters. The position peaked at $35.3M in Q4 2020. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.
- Morgan Stanley reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
- Morgan Stanley sold 467,442 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $15.8M.
- Morgan Stanley first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 12 quarters.
- Morgan Stanley's Constellation Pharmaceuticals, Inc. position peaked at $35.3M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.
Based on Morgan Stanley's 13F filing for Q3 2021, filed 15 Nov 2021.